Design Therapeutics (DSGN) Revenue (Gross) (2024 - 2026)

Design Therapeutics' Revenue (Gross) history runs 3 years deep, the most recent figure standing at $2.1 million for Q1 2026.

• In Q1 2026, Revenue (Gross) fell 23.42% year-over-year to $2.1 million; the TTM figure through Mar 2026 stood at $9.0 million (down 25.9% YoY), while the FY2025 annual figure was $9.7 million, down 24.38% from the prior year.
• Revenue (Gross) came in at $2.1 million for Q1 2026 at Design Therapeutics, down from $2.2 million in the prior quarter.
• In the past five years, Revenue (Gross) ranged from a high of $3.3 million in Q1 2024 to a low of $2.1 million in Q1 2026.
• A 3-year average of $2.7 million and a median of $2.7 million in 2025 frame the typical range for Revenue (Gross).
• On a YoY basis, Revenue (Gross) climbed as much as 17.97% in 2025 and fell as far as 28.62% in 2025.
• Design Therapeutics' Revenue (Gross) stood at $3.0 million in 2024, then retreated by 28.62% to $2.2 million in 2025, then dropped by 4.7% to $2.1 million in 2026.
• According to Business Quant data, Revenue (Gross) over the past three periods registered $2.1 million, $2.2 million, and $2.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison